Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

ducts with strong intellectual property and exciting growth prospects. We continue to increase the global reach of our business, and now have a presence in 26 countries worldwide compared to nine countries four years ago.

We have also developed a promising pipeline with encouraging recent news. With the receipt of a Complete Response Letter from the US Food and Drug Administration ("FDA") for INTUNIV, we are confident that we will quickly come to agreement on the final wording of the product label and will launch in the fourth quarter of 2009 as planned. We are also initiating Phase 2 pilot clinical trials to assess the efficacy and safety of VYVANSE in non ADHD ("Attention Deficit Hyperactivity Disorder") indications. Our HGT pipeline has been strengthened by positive results from our trial of velaglucerase in naïve Gaucher patients. A treatment protocol for early access has been approved by the FDA and the agency has approved Fast Track designation for the product. Rolling review of the New Drug Application ("NDA") has started.

Our core portfolio has made good progress in the quarter. We are pleased with the performance of VYVANSE as it has retained market share during the historically quieter summer vacation season in contrast to other branded ADHD treatments that have lost market share. We are anticipating the benefits of the back to school season for VYVANSE and are looking forward to increased sales momentum from our co-promote agreement with GSK for adult ADHD. We are also expecting further positive newsflow from our pipeline during the second half of this year.

Supported by pro-active cost management, our business is well placed to deliver on our unchanged guidance framework for 2009 and looking ahead we reiterate our aspiration of growing sales in the mid-teens range on average between 2009 and 2015."

    Second Quarter 2009 Unaudited Results

                                  
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... Boston, MA (PRWEB) , ... August 27, 2015 , ... ... the United States, ranking iLab Solutions as number 1,361 in growth for the three ... part of the top 0.1% fastest-growing privately held organizations in the country. , ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... Sanofi-aventis announced,today that the anticoagulant Clexane(R) ... in Japan by the Ministry of Health, ... thromboembolism (VTE) in patients,undergoing orthopaedic surgery of ... total knee replacement and hip fracture surgery., ...
... MNKD ), focused on discovering, developing and,commercializing treatments for ... the Wachovia Healthcare Conference on January 30, 2008 at,2:00 ... Interested parties can access a link to the ... section of the Company,s website at, http://www.mannkindcorp.com . A ...
... Jan. 25 Cephalon, Inc., (Nasdaq:,CEPH) today announced ... has,accepted the company,s supplemental New Drug Application (sNDA) ... of,breakthrough pain in opioid-tolerant patients with chronic pain. ... will convene an advisory,committee panel on May 6, ...
Cached Biology Technology:Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 2Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 3
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... julho de 2015 A 10 a. ... realizada pela BGI de 22-25 de outubro de 2015, em ... A conferência está celebrando seu 10 o. aniversário este ... tornou uma das reuniões mais influentes do mundo no ... dinâmicos, entusiastas e prazerosos. A ICG-10 ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... Academy of Sciences will host the Fifth Annual ... design of oligosaccharides and proteins for materials and ... on the following areas: (1) synthetic and biosynthetic ... these macromolecules in materials science and glycobiology, (2) ...
... Kidney stones strike an estimated 1 million Americans each year, ... is among the worst known to man (or woman). ... Medicine in St. Louis provides evidence to explain why some ... Their discovery opens the door to finding effective drug treatments ...
... Concordia University is bringing us one step closer to clean ... a battery-like enzyme can store energy from seconds to hours, ... Chemical Society shows. Concordia Associate Professor Lszl Klmn ... graduate students Sasmit Deshmukh and Kai Tang has been ...
Cached Biology News:Kidney stone mystery solved 2Kidney stone mystery solved 3Nature's billion-year-old battery key to storing energy 2
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... the Flp-In System creates isogenic cell ... levels of the protein of interest. ... Figure 3 (click link below). In ... chloramphenicol-acetyl transferase (CAT) was subcloned into ...
... solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, p-xylene, dimethyl sulfoxide, freon ... * Range: 12-position switchable: ... ... ...
Biology Products: